The Burden of Disease and the Evolving Landscape in Hepatitis C Therapy CME

Author Information and Disclosures

Release Date: January 29, 2008; Valid for credit through January 29, 2009

Credits Available
Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™ for physicians

The content of this CME activity, "The Burden of Disease and the Evolving Landscape in Hepatitis C Therapy," was developed by the faculty.

To participate in this activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Vertex
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Explore the impact of the overall liver disease burden attributable to hepatitis C and the impact of complications/comorbidities associated with hepatitis C virus (HCV) infection
  2. Discuss the major challenges in the treatment of patients with chronic hepatitis C, with a view toward how application of the evolving therapeutic arsenal may help address these challenges
  3. Explore current trends in the management of patients with hepatitis C, including current and emerging therapies, with a focus on new therapies (STAT-C) on the horizon
  4. Assess the potential of emerging therapeutic strategies for hepatitis C on the basis of early data, with a view toward the efficacy of the protease and polymerase inhibitors in enhancing treatment response and long-term outcome in HCV-infected patients
Authors and Disclosures

Nancy S. Reau, MD
Disclosure: Nancy S. Reau, MD, has disclosed that she has received grants for educational activities from Gilead. Dr. Reau has also disclosed that she has served as an advisor or consultant to Bristol-Myers Squibb and Gilead.


F. Fred Poordad, MD
Disclosure: F. Fred Poordad, MD, has disclosed that he has received grants for clinical research from Gilead, Schering, Bristol-Myers Squibb, Roche, Valeant, Novartis, Intarcia, Vertex, and GlaxoSmithKline. Dr. Poordad has also disclosed that he has received grants for educational activities from Gilead, Schering, Bristol-Myers Squibb, Roche, Valeant, Vertex, and Novartis. Dr. Poordad has also disclosed that he has served as an advisor or consultant to Gilead, Vertex, and Schering.


Maria L. Gaiso, PhD
Disclosure: Maria L. Gaiso, PhD, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.